Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ServiceNow Inc (NOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ServiceNow Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while ServiceNow Inc trades at $107.15 (market cap $114.20B). The key difference: ServiceNow Inc is far larger — about 25.4× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | NOW | |
|---|---|---|
Market Cap | $4.49B | $114.20B |
Sector | Health | Technology |
52-Week High | $28.06 | $204.60 |
52-Week Low | $20.06 | $83.00 |
Enterprise Value | $3.69B | $111.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ServiceNow (NOW) trades at $107.93, up 1.51% today, with a bullish technical outlook supported by positive moving averages. The company reported strong revenue growth to $13.28 billion in 2025 and has beaten earnings estimates in three of the last four quarters. Recent news highlights AI-driven growth potential and conference presentations, while analyst consensus remains strongly bullish with an 85.51% buy rating.
The outlook for NOW is positive due to robust fundamentals and AI adoption, but high valuation multiples (P/E 64.24) pose a risk if growth slows. Upside to the $136.43 price target offers potential, yet investors face volatility from competitive pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
